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ABSTRACT  
Objective: The work presents a sensitive, selective and rapid determination of lapatinib, a potent anticancer drug in human plasma by liquid 
chromatography-tandem mass spectrometry.  
Methods: Liquid-liquid extraction of lapatinib and lapatinib-d4, added as an internal standard (IS) was carried out from 100 µl plasma sample. 
Chromatographic analysis was performed on ACE C18 (100 mm × 4.6 mm, 5 µm) column using 10 mmol ammonium formate buffer (pH 3.5) and 
acetonitrile (10:90, v/v) as the mobile phase. The precursor ion → product ion transitions for lapatinib (m/z 581.1 → 365.2) and IS (m/z 585.1 → 
365.0) were monitored on a triple quadrupole mass spectrometer in the positive electrospray ionization mode. The method was validated in 
accordance with the US FDA guidelines.  
Results: A linear concentration range was established from 2.50-2500 ng/ml for lapatinib. The intra-batch and inter-batch precision were ≤ 4.81 %. The 
recovery of lapatinib and IS from plasma samples ranged from 88.7 to 95.8 % and 85.9 to 96.5 % respectively. The accuracy and precision (% CV) for the 
stability of lapatinib under different storage conditions showed a variation from 95.2 to 102.2 % and 1.19 to 4.35 % respectively at low and high QC 
levels. Under optimized chromatographic conditions, the retention time for lapatinib was 1.406 min with a total run time of 2.5 min for each sample. 
Conclusion: The validation results demonstrate that the method is simple, accurate, precise and reproducible. The developed method can be 
readily used for pharmacokinetics/bioequivalence studies in patients as well as healthy subjects.  
Keywords: Lapatinib, Lapatinib-d4, Liquid chromatography-tandem mass spectrometry, Human plasma, Sensitive, High-throughput.  
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INTRODUCTION 
Lapatinib is an orally active and a dual tyrosine kinase (TK) 
reversible inhibitor of epidermal growth factor receptor 
(ErbB1/EGFR) and human epidermal growth factor receptor 2 
(ErbB2/HER2). These ErbB receptors play a major role in tumor cell 
growth and survival and are therefore key therapeutic targets [1]. 
Lapatinib acts intracellularly by reversibly binding to the 
cytoplasmic ATP-binding site of the kinase and at the same time 
blocking receptor phosphorylation and activation. As a result, it 
prevents ensuing downstream signaling events.  
The ability of lapatinib to specifically inhibit ErbB1 and ErbB2 
receptors is unique compared to other small molecule TK 
inhibitors like erlotinib and gefitinib [2, 3]. Two effective 
combinations of lapatinib with capecitabine/letrozole have been 
approved by the US Food and Drug Administration for the 
treatment of metastatic HER2 positive breast cancer and for 
postmenopausal women with HER2 & estrogen receptor positive 
breast cancer respectively [4].  
Currently, lapatinib is available as a 250 mg tablet formulation and is 
recommended as a single dose at least 1.0 h before or after a meal 
[1]. However, it has been demonstrated that food increases the 
bioavailability of the drug after oral administration [5]. Further, the 
peak plasma concentration reaches within 3-6 h post dosing. 
Lapatinib is mainly bound to plasma albumin (>99%) and has a high 
volume of distribution (>2200 L), suggesting good drug distribution 
[6]. Lapatinib exhibits large inter-individual variation in 
pharmacokinetics due to the contribution of several metabolizing 
enzymes and transporters involved in the process of absorption and 
disposition. Thus to support efficient lapatinib therapeutic drug 
monitoring and clinical pharmacokinetics it is essential to develop 
highly sensitive, rapid and reliable methods to monitor the plasma 
concentration of lapatinib in patient samples.  
Several methods are described in the literature for the individual [7-
10] as well as the simultaneous determination of lapatinib [11-18] 
with other TK inhibitors in human plasma [7-10, 12-18] or cellular 
samples [11]. These methods have mainly used liquid 
chromatography with mass spectrometry detection for the analysis 
of lapatinib except one report which utilizes UV as the detector [9]. 
Some of these developed methods are either less sensitive (≥ 50 
ng/ml) [7, 15, 17, 18], have higher retention time for lapatinib (≥ 3.0 
min) [8, 10, 12, 15-18] or require large plasma volume for 
processing (≥ 250 µl) [8, 10, 13]. Moreover, it has been emphasized 
that the use of isotope-labeled IS is essential to minimize variation in 
the recovery of anticancer drugs [8]. The comparative features of 
liquid chromatography-mass spectrometric (LC-MS/MS) method 
developed for lapatinib in human plasma is presented in table 1. 
Thus, the primary objective of the work was to develop a simple 
extraction procedure with reduced sample volume for processing 
using a deuterated IS for precise and quantitative recovery. This was 
essential as lapatinib is an anticancer drug and is estimated clinically 
mainly in patients and therefore, it is important to minimize blood 
loss during subject sample analysis. The other aspect was to 
optimize chromatographic run time with adequate retention on a 
reversed phase column to maximize throughput. The developed 
method was fully validated as per current regulatory guidelines 
especially for matrix effect and stability of lapatinib under different 
conditions. 
MATERIALS AND METHODS 
Chemicals and reagents 
Working standards of lapatinib (99.5%) and lapatinib-d4 (IS, 98.9%) 
were purchased from TLC Pharmachem (Toronto, Canada). HPLC 
grade acetonitrile and methanol were obtained from J. T. Baker 
(Mumbai, India). Guaranteed reagent grade formic acid, ammonium 
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formate, ammonia solution (30 %) and methyl tert-butyl ether were 
purchased from Merck Specialties Pvt. Ltd., (Mumbai, India). Water 
was purified using Milli-Q water purification system from Millipore 
(Bangalore, India). Blank human plasma was procured from 
Supratech Micropath Lab (Ahmedabad, India) and was stored at–70 °C 
until use. 
  
Table 1: Comparative summary of liquid chromatography-mass spectrometry methods developed for lapatinib in human plasma 
S. 
No. 
Extraction procedure; internal standard; mean 





Retention time and run 
time (min)  
Ref.  
1 SPE on Strata X cartridge; lapatinib-d6; 75  100  100-10000 1.62 and 3.5  7 
2 LLE with ethyl acetate; lapatinib-d3; 82.7  250  5.0-5000  4.4 and 10.0  8 
3 LLE with MTBE; lapatinib-d7, [13]C; 78.6  250  5.0-800 3.5 and 11.0  10 
4 PP with ACN; imatinib-d8; 103.4  a 100  5.0-5000 8.77 and 15.0 12 
5 SPE on Oasis MCX cartridge; sorafenib-d4; 90.3 a 300  10.0-5000  1.84 and 3.0  13 
6 PP with MeOH; lapatinib-d4; -- a 20 4.55-2000 -- 14 
7 PP with MeOH; imatinib-d8; 99.3 a 100  50-5000 6.6 and 12.0 15 
8 PP with ACN; lapatinib-d7, [13]C; 67.2 a 50   20-10000  4.6 and 10.0 16 
9 PP with ACN; imatinib-d8; 85-90 a 50 100-5000 3.2 and 5.5 17 
10 PP with ACN; imatinib-d8; 84-101.2 a 50 50-3500 3.28 and 6.0 18 
11 LLE with methyl tert-butyl ether; lapatinib-d4; 91.9 % 100  2.5-2500 1.04 and 2.5 PM 
a
 
Together with other tyrosine kinase inhibitors; MTBE: methyl tert-butyl ether; ACN: acetonitrile; MeOH: methanol; SPE: solid phase extraction; 
LLE: liquid-liquid extraction; PP: protein precipitation; PM: present method 
LC-MS Instrumentation and conditions 
A Shimadzu HPLC system (Tokyo, Japan) consisting of binary solvent 
mixer, sample manager, and column manager was used for setting the 
reverse-phase liquid chromatographic conditions. The separation of 
lapatinib and IS was performed on ACE C18 (100 mm × 4.6 mm, 5 µm) 
column maintained at 40 °C in a column oven. The mobile phase 
consisted of 10 mmol ammonium formate buffer (pH 3.5, adjusted 
with formic acid): acetonitrile (10:90, v/v) and was delivered 
isocratically at a flow rate of 1.0 ml/min, with 90 % flow splitting. The 
flow directed to the ion spray interface was equivalent to 100 μl/min. 
The auto sampler temperature was maintained at 5 °C.  
Ionization and detection of lapatinib and IS were performed on a 
triple quadrupole mass spectrometer, MDS SCIEX, API4000 (Applied 
Biosystems, Canada), equipped with electrospray ionization and 
operating in positive ion mode. Quantification was performed using 
multiple reaction monitoring (MRM) to monitor precursor → 
product ion transitions of m/z 581.1 → 365.2 and m/z 585.1 → 365.0 
for lapatinib and IS respectively.  
The source dependent parameters maintained for lapatinib and IS 
were curtain gas: 25.0 psig, ion spray voltage: 5500 V, temperature: 
400.0 °C, nebulizer gas (GS1): 60.0 psig, heater gas (GS2): 40.0 psig 
and collision gas: 10.0 psig. Optimum values set for compound 
dependent parameters (MRM file parameters) were declustering 
potential: 42.0 V, entrance potential: 10.0 V, collision energy: 45.0 eV 
and collision cell exit potential: 13.0 V. The dwell time was set at 200 
ms. Analyst software version 1.4.2 was used to control all 
parameters of HPLC and MS. 
Preparation of standard stock, calibration standards, and 
quality control samples  
The standard stock solution of lapatinib (1000 µg/ml) was 
prepared by dissolving the requisite amount in methanol. Further, 
an intermediate solution of lapatinib (10.0 µg/ml) was prepared in 
methanol: water (50:50, v/v). Calibration standards (CSs) and 
quality control (QC) samples were prepared by spiking blank 
plasma with working solution prepared from intermediate 
solution. CSs were made at the following concentrations 2.50, 5.00, 
10.0, 20.0, 40.0, 100, 250, 625, 1250 and 2500 ng/ml while the QC 
samples were prepared at four concentration levels, 2000 ng/ml 
(HQC, high quality control), 1000 and 70.0 ng/ml (MQC-1 and 2, 
medium quality control) and 7.5 ng/ml (LQC, low quality control). 
Stock solution (1.0 mg/ml) of lapatinib-d4 was prepared by 
dissolving 10 mg in 10 ml methanol. An aliquot of 50 µl of this 
solution was further diluted to 50 ml in acetonitrile: water (50:50, v/v) 
to obtain a working solution of 1.0 µg/ml. The stock solutions were 
stored at 5 °C, while the CSs and QC samples were kept at–70 °C until 
use.  
Sample preparation 
Prior to analysis, all CSs and QC samples were thawed and allowed 
to equilibrate at room temperature. To an aliquot of 100 µl of spiked 
plasma sample, 50 µl working solution of IS was added and vortexed 
for 1.0 min. Further, 50 µl of ammonia solution (5.0 % in water) was 
added and vortexed again for 1.0 min. Samples were then extracted 
with 2.0 ml methyl tert-butyl ether at 50 rpm for 10 min, followed by 
centrifugation at 4000 rpm at 10 °C for 5 min. The supernatant was 
transferred in pre-labeled tubes, and the samples were evaporated 
to dryness under nitrogen at 40 °C. The dried samples were 
reconstituted with 500 µl of mobile phase and 5 µl was used for 
injection in the chromatographic system.  
Method validation 
The method was validated as per the current regulatory 
requirements to establish the accuracy and precision of the method 
[19]. The details of the parameters studied were the same as our 
previous study [20]. System suitability experiment was performed 
by injecting six consecutive injections using an aqueous standard 
mixture of lapatinib and IS at the start of each batch to evaluate the 
precision in the measurement of area response and retention time. 
Precision (% CV) of system suitability test was observed in the range 
of 0.64 to 1.05 % for the retention time and 0.32 to 2.16 % for the 
area response. System performance was checked by measuring the 
signal to noise (S/N) ratio for the lowest concentration of lapatinib 
in the calibration curve. The signal to noise ratio for system 
performance was ≥ 26  for lapatinib. Carryover assessment was 
carried out through the following sequence of injections, extracted 
blank plasma, upper limit of the quantification (ULOQ) sample, two 
extracted blank plasma samples, lower limit of quantification 
(LLOQ) sample and extracted blank plasma at the beginning of the 
batch. 
The selectivity of the method was investigated by analyzing eight 
individual blank plasma sources (5 normal K3
Five calibration curves with ten non-zero concentrations were 
prepared to determine the linearity of the method. The peak area 
ratio (lapatinib/IS) response obtained through multiple reaction 
monitoring vs. concentration plot was drawn using linear regression 
EDTA, 1 heparinized, 1 
haemolysed and 1 lipemic). Each blank plasma sample was checked 
for interference by comparing with spiked plasma samples at LLOQ 
concentration. Method was also assessed for the interference of 
some commonly used medications by human volunteers. This 
included domperidone, paracetamol, ranitidine, diclofenac, caffeine, 
acetylsalicylic acid and ibuprofen. Their stock solutions (100 µg/ml) 
were prepared in methanol: water (50:50, v/v), spiked with the 
sample and analyzed to check for any interference in the 
quantification of lapatinib.  
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with 1/x2
The stability of analytes in plasma was examined at LQC and HQC 
levels under different study conditions: bench top at 25 °C, freeze-
thaw at-20 °C and-70 °C, wet extract (autosampler) at 5 °C and 25 °C, 
dry extract at 5 °C, and long-term stability at-20 °C and-70 °C 
respectively. The area ratio response (labatinib/IS) of stability 
samples was compared against freshly prepared comparison 
standards with identical concentration. The procedure also included 
an evaluation of short-term (25 °C) and long term (5 °C) stability of 
lapatinib and IS in stock and working solutions.  
 weighting. Intra-day accuracy and precision were 
evaluated by measuring the plasma concentration of lapatinib on the 
same day. The analytical run consisted of a calibration curve and six 
replicates of QC samples at five concentration levels. The inter-day 
accuracy and precision were assessed by analysis of five separate 
precision and accuracy batches on three consecutive days. The 
reinjection reproducibility for retention time was also checked by 
reinjection of one entire analytical batch of 80 samples.  
The extraction recovery of lapatinib and IS from human plasma was 
evaluated in six replicates by comparing the mean peak area response 
of pre-extraction spiked samples to those of post-extraction spiked 
samples. Matrix effect expressed as matrix factors (MFs) was assessed 
by comparing the mean area response of post-extraction spiked 
samples with a mean area of solutions prepared in mobile phase 
solutions (neat standards) with identical concentration. The relative 
matrix effect was determined by assessment of precision (% CV) 
values for slopes of calibration lines from eight different plasma lots 
[21]. For qualitative assessment of matrix effect, post-column infusion 
experiment was performed by infusing a standard solution of lapatinib 
(2500 ng/ml) and IS (1000 ng/ml) post column at a constant flow rate 
of 10 µl/min. An aliquot of 5 µl of extracted control blank plasma 
sample/mobile phase was then injected into the column by the 
autosampler and the chromatograms were acquired. 
The ruggedness of the method was tested on two different columns 
of the same make but different batch numbers and also by 
employing different analysts using two precision and accuracy 
batches. Further, dilution reliability of the method was also studied 
by analyzing six replicates samples prepared as spiked standard at 2 
times ULOQ concentration (5000 ng/ml) after five and ten-fold 
dilution respectively. The precision and accuracy for dilution 
reliability were determined by comparing the samples against 
freshly prepared calibration curve standards.  
RESULTS AND DISCUSSION 
LC-MS/MS method optimization 
Mass spectrometry settings were carried out in the positive 
electrospray ionization mode due to the presence of secondary 
amino groups which can be readily protonated under acidic 
conditions in the mobile phase. Initially, the Q1 MS spectra obtained 
by infusing 500 ng/ml solutions of lapatinib and IS contained 
abundant protonated precursor ions at m/z 581.1 and 585.1 
respectively (fig. 1 and fig. 2). The most consistent and stable 
product ions in Q3 MS spectra for lapatinib and IS were observed at 
m/z 365.2 and 365.0 by applying 45 eV collision energy.  
These identical product ions were formed as a result of the 
elimination of methyl sulfonyl ethyl groups from their respective 
precursor ions as shown in fig. 1 and fig. 2. The source dependent 
and compound dependent parameters were suitably optimized to 
obtain a consistent and sufficient response for lapatinib. A dwell 
time of 200 ms afforded a sufficient number of data points for the 
quantitation of lapatinib, avoiding cross talk between lapatinib and 
IS with identical product ions. Under the optimized conditions, the 
cross talk experiment showed no detectable change in the peak area 
of lapatinib and IS at their respective MRMs. 
 
 
Fig. 1: Mass spectra of (A) Q1 precursor ion and (B) Q3 product ion of lapatinib in the positive electrospray ionization mode 
 
Chromatographic conditions were optimized by careful selection of 
mobile phase composition (aqueous and organic ratio), pH and flow 
rate to obtain proper retention, symmetric peak shape, and adequate 
response. Three reversed phase columns having identical 
dimensions were studied during initial trials namely ACE C18 (100 
mm × 4.6 mm, 5 µm), Hypersil C18 (100 mm × 4.6 mm, 5 µm) and 
Gemini C18 (100 mm × 4.6 mm, 5 µm). The concentration of 
ammonium formate (pH 3.0-5.5, adjusted with formic acid) in the 
range of 2.0-10 mmol was critically examined to get symmetric peak 
shape and better analyte response. Additionally, the flow rate was 
varied from 0.6-1.0 ml/min to minimize any possible interference at 
the retention time of lapatinib. The results obtained on all three 
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columns was comparable in terms of chromatographic run time and 
response but the best peak shape was found on ACE C18 column at a 
flow rate of 1.0 ml/min using 10 mmol ammonium formate buffer 
(pH 3.5): acetonitrile (10:90, v/v) as the mobile phase. The 
reproducibility of retention time for lapatinib expressed as % CV 
was ≤ 0.82 % for the entire batch of 80 samples on the same column. 
The selectivity of the method is evident from fig. 3 which shows the 
chromatograms of double blank plasma, blank plasma spiked with 
IS, lapatinib and IS at LLOQ and ULOQ concentration. There was no 
interference of endogenous components at the retention time of the 
lapatinib and IS. Similarly, none of the commonly used medications 
by human volunteers interfered at the retention of lapatinib and IS. 
Wu et al. [8] have critically examined the impact of isotope labeled 
and non-isotope labeled IS and found that only isotope labeled IS 
could correct for variability in the recovery of lapatinib from patient 
samples. Thus, we employed a deuterated analog, lapatinib-d4 as IS 
in the present work, which gave acceptable accuracy and precision 
in the determination of lapatinib from plasma samples.  
Ion suppression effect from the LLE extracted blank human plasma 
and mobile phase solution after post-column infusion of lapatinib 
and IS is depicted in fig. 4. The results demonstrate the absence of 




Fig. 2: Mass spectra of (A) Q1 precursor ion and (B) Q3 product ion of lapatinib-d4, internal standard in the positive electrospray 
ionization mode 
 
Lapatinib is a non polar hydrophobic drug having log P>4.6 [7] and 
is slightly basic in nature (pKa
The results showed that base treated samples afforded more 
consistent recovery (45-54 %) as compared to acid pretreated (41-
67 %) or untreated samples (38-56 %). However, to have a 
quantitative and precise recovery of lapatinib we switched over to 
LLE under alkaline conditions (30 % ammonia solution) to render 
the drug more hydrophobic for better extraction. Indeed, the results 
thus obtained with methyl tert-butyl ether were much superior 
compared to SPE. The mean recovery across three QC levels was 
91.9 % (varying from 88.7 to 95.8 %), which is higher and more 
consistent than two previous studies using ethyl acetate [8] and 
methyl tert-butyl ether [10] as extraction solvents. 
 ~ 7.2) [11]. Thus, in principle either, 
liquid-liquid extraction (LLE) or solid-phase extraction (SPE) on 
non-polar reversed phase C18 cartridges can be used as reported 
previously [7, 8, 10, 11]. We therefore, tried both these techniques 
using n-hexane, ethyl acetate methyl tert-butyl ether and 
dichloromethane as extraction solvents for LLE and Waters Oasis 
HLB and Phenomenex Strata-X cartridges for SPE. On SPE, trials 
were performed after pre-treatment of the plasma samples with an 
acid (acetic acid/formic acid), base (30 % ammonia) and also under 
neutral conditions. Elution conditions were also optimized using 
acetonitrile/methanol and their mixture together with an acidic 
buffer (formic acid-ammonium formate).  
Validation results 
Selectivity and carryover  
Selectivity of the assay was assessed in eight different batches of 
blank plasma to establish that quantitation of lapatinib is unaffected 
by the presence of biological matrix and other interfering 
components. There was no significant interference at the retention 
time of the lapatinib in any of the batches studied. The carry-over 
evaluation was performed before and after each analytical run to 
ensure that it does not influence the accuracy and the precision of 
the proposed method. The column and autosampler carry-over 
evaluation showed negligible carry over in blank plasma (≤ 0.24 % 
of LLOQ area response) after subsequent injection of ULOQ sample.  
Linearity, accuracy and precision 
Regression analysis was carried out to assess the linearity between 
the peak area ratio (lapatinib/IS) and lapatinib concentration. All 
calibration curves were linear (r2 ≥ 0.9985) through the studied 
concentration range of 2.50-2500 ng/ml of lapatinib. The mean 
linear equation for calibration curve concentrations was y = 
(0.0034±0.0001)x + (0.0033±0.0012). The accuracy and precision 
(% CV) observed for the calibration curve standards ranged from 
96.40 to 102.75 % and 1.37 to 4.12 % respectively for lapatinib. The 
limit of detection (LOD) and LLOQ of the method was 1.0 ng/ml and 
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2.50ng/ml (% CV<20) at S/N ratio of 12 and 26 respectively. The 
intra-batch and inter-batch precision and accuracy results across 
five QC levels are shown in table 2. The intra-batch precision (% CV) 
ranged from 1.43-2.56 % and the accuracy was within 97.8-105.5 % 
for lapatinib. Similarly for inter-batch experiments, the precision 
varied from 1.39-4.81 % and the accuracy was within 97.7-105.0 %. 
 
 
Fig. 3: MRM ion-chromatograms of (A) double blank plasma (without lapatinib and lapatinib-d4), (B) blank plasma and lapatinib-d4 (m/z 
585.1 → 365.0), (C) lapatinib (m/z 581.1 → 365.2) at LLOQ and lapatinib-d4, (D) lapatinib at ULOQ and lapatinib-d4 
 
 
Fig. 4: Matrix effect profiles after post-column infusion of lapatinib (250 ng/ml) and lapatinib-d4 (1000 ng/ml) while injecting extracted 
blank plasma and mobile phase solution 
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Precision (% CV) Accuracy 
(%) 
2000 2020 1.43 101.0 2046 2.05 102.3 
1000 1055 1.87 105.5 1036 1.39 103.6 
75.0 77.8 1.79 103.7 78.6 3.63 105.0 
7.50 7.33 2.36  97.8 7.40 3.13 98.7 
2.50 2.55 2.56 102.0 2.44 4.81 97.7 
 n: number of replicates; CV: coefficient of variation 
 
Extraction recovery and matrix effect 
The extraction recovery and matrix effect results for lapatinib and IS 
are presented in table 3 and 4 respectively. The extraction recovery 
for lapatinib and IS varied from 88.7 to 95.8 % and 85.9 to 96.5 % 
respectively across QC levels. The potential impact of matrix effect 
on the quantification of lapatinib was expressed as matrix factor 
(MF). MFs can be determined from the peak area response of 
lapatinib and IS separate while the ratio of the two factors gives the 
IS-normalized MF.  
The IS-normalized MFs using stable-isotope-labeled IS should be 
close to unity because of the similarities in the chemical properties 
and elution times. The IS-normalized MFs ranged from 0.974-1.044. 
 
Table 3: Extraction recovery for lapatinib 
QC level 
(nominal conc., ng/ml) 
Mean area response (n = 6) Extraction recovery, % (B/A) 
A (spiking  
after extraction) 
B (spiking before extraction) 
LQC (7.50) 30876 27387 88.7 (85.9)a 
MQC-2 (75.0) 303155 274052 90.4 (92.1)
MQC-1 (1000) 
a 
3942066 3776499 95.8 (94.6)
HQC (2000) 
a 
7829487 7250105 92.6 (96.5)a 
a
 
Mean recovery of lapatinib-d4; n: number of replicates  
Table 4: Matrix effect results for lapatinib 
QC level 
(nominal conc., ng/ml) 
Mean area response (n = 6) Matrix factor 
A (spiking  
after extraction) 





LQC (7.50) 30876 31094 0.993 1.002 0.991 
MQC-2 (75.0) 303155 306837 0.988 1.014 0.974 
MQC-1 (1000) 3942066 3812443 1.034 0.990 1.044 
HQC (2000) 7829487 7900592 0.991 0.987 1.004 
IS: internal standard, lapatinib-d4; n: number of replicates  
Further, matrix effect needs to be checked in lipemic and haemolysed plasma samples in addition to normal K3
Table 5: Stability of lapatinib under different conditions (n = 6) 
EDTA plasma. The coefficient of 
variation (% CV) of the slopes of calibration lines for relative matrix effect in eight different plasma lots was 2.07 %, which is within the acceptance 
criteria of 3.0 % [21]. 
Storage conditions 
 
Nominal conc.  
(ng/ml) 
Mean stability  
Sample (ng/ml)±SD 
Accuracy (%)  Precision (% CV) 
Bench top stability  
at 25 °C, 12 h 
2000 2043±59 102.2 2.92 
7.50 7.36±0.32 98.1 4.35 
Freeze & thaw stability  
at-20 °C, 5 cycles 
2000 2035±45 101.7 2.21 
7.50 7.42±0.27 98.9 3.64 
Freeze & thaw stability  
at-70 °C, 5 cycles 
2000 2014±24 100.7 1.19 
7.50 7.31±0.19 97.5 2.60 
Auto sampler stability  
at 5 °C, 24 h 
2000 1976±38 98.8 1.92 
7.50 7.45±0.22 99.3 2.95 
Dry extract stability  
at 5 °C, 12 h 
2000 1947±64 97.4 3.28 
7.50 7.21±0.15 96.1 2.11 
Wet extract stability  
at 25 °C, 12 h 
2000 1968±27 98.4 1.37 
7.50 7.33±0.17 97.7 2.32 
Long term stability  
at-20 °C, 92 d 
2000 2029±35 101.5 1.72 
7.50 7.39±0.12 98.5 1.62 
Long term stability  
at-70 °C, 92 d 
2000 1989±56 99.5 2.81 
7.50 7.14±0.28 95.2 3.92 
 SD: standard deviation; n: number of replicates 
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Stability, dilution reliability and method ruggedness  
Samples kept for short term and long term stock and working 
solution stability remained unaffected up to 20 h and 66 d 
respectively for lapatinib and IS. Bench top stability of lapatinib in 
plasma was established up to 12 h and for a minimum of five freeze 
and thaw cycles at–20 °C and–70 °C. Autosampler stability (wet 
extract) of the spiked quality control samples maintained at 5 °C was 
determined up to 24 h without significant loss of lapatinib. Spiked 
plasma samples stored at–20 °C and–70 °C, for long term stability 
experiment were found stable for a minimum period of 92 d. 
For method ruggedness, the precision (% CV) and accuracy values 
for different columns and analysts ranged from 0.88 to 1.68 % and 
99.3 to 104.0 % respectively for lapatinib at five QC levels. The 
precision (% CV) for dilution reliability of 1/5th (1000 ng/ml) and 
1/10th
1. Oakman C, Pestrin M, Zafarana E, Cantisani E, Di Leo A. Role of 
lapatinib in the first-line treatment of patients with metastatic 
breast cancer. Cancer Manage Res 2010;2:13-25. 
 (500 ng/ml) of 5000 ng/ml solution was between 1.68 and 
2.48 %, while the accuracy results were within 98.4 and 103.1 % 
respectively, which is within the acceptance limit of 15 % for 
precision (% CV) and 85 to 115 % for accuracy. 
CONCLUSION 
The present work successfully demonstrates a sensitive, rapid and 
precise method for determination of lapatinib from endogenous 
plasma matrix. The selectively of this bioanalytical method enhances 
its utility for clinical pharmacokinetic studies. The salient features 
include the use of small plasma sample for analysis, quantitative and 
precise recovery, high sensitivity (2.50 ng/ml) and high throughput 
(2.5 min). Use of deuterated IS minimizes inter-individual variability 
in the recovery of lapatinib following efficient LLE approach under 
alkaline conditions. Finally, the method shows good accuracy and 
precision as evident from the results of all validation parameters.  
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